Melissa A Bender

Summary

Affiliation: New York University School of Medicine
Country: USA

Publications

  1. pmc Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India
    Melissa A Bender
    Divisions of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Infect Dis 50:416-25. 2010
  2. pmc When to start antiretroviral therapy in resource-limited settings
    Rochelle P Walensky
    Massachusetts General Hospital, Brigham and Women s Hospital, Harvard University Medical School, Harvard School of Public Health, and Boston University School of Public Health, Boston, Massachusetts 02114, USA
    Ann Intern Med 151:157-66. 2009
  3. pmc Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy
    Kenneth A Freedberg
    Divisions of General Medicine and Infectious Disease and the Partners AIDS Research Center, Massachusetts General Hospital, Boston, MA, USA
    AIDS 21:S117-28. 2007
  4. pmc Scaling up antiretroviral therapy in South Africa: the impact of speed on survival
    Rochelle P Walensky
    The Divisions of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    J Infect Dis 197:1324-32. 2008
  5. pmc WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers
    Andrea L Ciaranello
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 6:e20224. 2011
  6. pmc The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis
    Jason R Andrews
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, 02114, USA
    AIDS 26:987-95. 2012
  7. pmc First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial
    Andrea L Ciaranello
    Division of Infectious Disease, Massachusetts General Hospital, Boston, 02114, USA
    AIDS 25:479-92. 2011

Detail Information

Publications7

  1. pmc Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India
    Melissa A Bender
    Divisions of General Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
    Clin Infect Dis 50:416-25. 2010
    ..We evaluated the clinical outcomes and cost-effectiveness of first-line ART using tenofovir in India, compared with current practice using stavudine or zidovudine...
  2. pmc When to start antiretroviral therapy in resource-limited settings
    Rochelle P Walensky
    Massachusetts General Hospital, Brigham and Women s Hospital, Harvard University Medical School, Harvard School of Public Health, and Boston University School of Public Health, Boston, Massachusetts 02114, USA
    Ann Intern Med 151:157-66. 2009
    ..The results of international clinical trials that are assessing when to initiate antiretroviral therapy (ART) will not be available for several years...
  3. pmc Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy
    Kenneth A Freedberg
    Divisions of General Medicine and Infectious Disease and the Partners AIDS Research Center, Massachusetts General Hospital, Boston, MA, USA
    AIDS 21:S117-28. 2007
    ..India has more than 5.7 million people infected with human immunodeficiency virus (HIV). In 2004, the Indian government began providing antiretroviral therapy (ART), and there are now an estimated 56 500 people receiving ART...
  4. pmc Scaling up antiretroviral therapy in South Africa: the impact of speed on survival
    Rochelle P Walensky
    The Divisions of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    J Infect Dis 197:1324-32. 2008
    ..Only 33% of eligible human immunodeficiency virus (HIV)-infected patients in South Africa receive antiretroviral therapy (ART). We sought to estimate the impact of alternative ART scale-up scenarios on patient outcomes from 2007-2012...
  5. pmc WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers
    Andrea L Ciaranello
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 6:e20224. 2011
    ..The Zimbabwean national prevention of mother-to-child HIV transmission (PMTCT) program provided primarily single-dose nevirapine (sdNVP) from 2002-2009 and is currently replacing sdNVP with more effective antiretroviral (ARV) regimens...
  6. pmc The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis
    Jason R Andrews
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, 02114, USA
    AIDS 26:987-95. 2012
    ..Such patients are usually screened by symptoms and sputum smear, which have poor sensitivity...
  7. pmc First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial
    Andrea L Ciaranello
    Division of Infectious Disease, Massachusetts General Hospital, Boston, 02114, USA
    AIDS 25:479-92. 2011
    ..nevirapine-based antiretroviral therapy (ART) among women previously exposed to single-dose nevirapine to prevent mother-to-child HIV transmission. However, lopinavir/ritonavir is 12 times costlier than nevirapine...